How Microbiome-based Therapies Can Help Your Patients
A healthy gut has a diverse range of microbes that help us digest the food we eat, produce special nutrients, and regulate our mood and immune system. Think of a healthy microbiome like a rain forest bursting with thousands of plant species, birds, and mammals, where they all play critical roles in maintaining a healthy, diverse and stable ecosystem. But modern diets, lifestyles, and other factors are slowly destroying this delicate ecosystem in our gut. This loss of microbial diversity and function is associated with a growing list of chronic health issues.
WATCH BiomeBank’s Chief Medical Officer Dr Samuel Costello talk about his experiences of using Microbial Therapies with patients.
Microbiome-based therapies have demonstrated that restoring a patient’s gut microbial ecology can effectively treat certain infectious and chronic diseases. This has traditionally been done by Faecal Microbial Transplantation (FMT) which involves transplanting the microbial community found in the gut of a healthy donor into a patient with chronic disease.
Clinical studies have repeatedly demonstrated that Faecal Microbial Transplantation (FMT) can effectively treat recurrent clostridioides difficile infection, a condition which causes severe diarrhoea and is becoming more common due to the widespread use of antibiotics.
This method of treatment has been shown to prevent recurrent infection in 81% – 96% of patients with minimal side effects. It has been shown to be superior to treatment of the infection with antibiotics alone, the current standard of care.
Current Treatment (Antibiotics) vs Faecal Microbial Transplantation (FMT)
Microbiome-based therapies are currently being studied as a treatment for other inflammatory diseases such as ulcerative colitis. In a randomised clinical trial published in JAMA, BiomeBank’s Chief Medical Officer Dr Samuel Costello and team demonstrated that FMT can induce clinical remission in patients with mild to moderate Ulcerative Colitis. A recent study in Lancet further demonstrated the role of microbiome-based therapies in treating ulcerative colitis (Haifer et al. 2022 Lancet).
Remission Rates for Placebo vs Orally delivered encapsulated FMT for Patients with Ulcerative Colitis
Orally delivered FMT
BiomeBank’s microbiome-based therapy is anticipated to be the first microbiome-based therapy approved as a biologic in the world. The product’s formulation includes encapsulated freeze-dried for oral delivery and syringe frozen for colonoscopy and enema delivery. We anticipate the encapsulated product to be available through hospitals and pharmacies shortly.
Our products are manufactured in a facility approved by Australia’s Therapeutic Goods Association (TGA), after a rigorous, quality controlled screening, and donation process. It is supplied to hospitals and clinics throughout Australia and can be administered by healthcare professionals.
Need more information or want to order our product for your patients?
Get in touch with our team.
*BIOMICTRA is a live biotherapeutic product distributed under the TGA transition provisions.
It’s intended use includes the treatment of recurrent clostridioides difficile infection and Ulcerative Colitis.
For healthcare professional use only.
Get a better understanding of your microbiome with our long read articles.